Racial and ethnic disparities in breast cancer rates by age: NAACCR Breast Cancer Project Sue A. JoslynMary L. FooteHolly L. Howe Report Pages: 97 - 105
An ecological study of the association of environmental chemicals on breast cancer incidence in Texas Yvonne M. CoyleLinda S. HynanAbu T.M. Minhajuddin Report Pages: 107 - 114
The importance of temporal effects in evaluating the prognostic impact of joint ERPR expression in premenopausal women with node-positive breast cancer Yandong OuyangDongguang LiMark Levine OriginalPaper Pages: 115 - 123
Transcription factor decoy against promoter C of estrogen receptor α gene induces a functional ERα protein in breast cancer cells Elisabetta LambertiniLetizia PenolazziRoberta Piva Report Pages: 125 - 132
Polymorphisms in the IGF-1 and IGFBP3 promoter and the risk of breast cancer Kerstin WagnerKari HemminkiAsta Försti Report Pages: 133 - 140
GREB1 is a critical regulator of hormone dependent breast cancer growth James M. RaeMichael D. JohnsonMarc E. Lippman Report Pages: 141 - 149
Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy Arti HurriaKelly BroganClifford Hudis Report Pages: 151 - 156
Cosmetic outcome of breast conserving therapy after sentinel node biopsy versus axillary lymph node dissection H.F.J. FabryB.M. ZonderhuisJ.R.M. Van der Sijp OriginalPaper Pages: 157 - 162
Antibiotic exposure and breast cancer in New Zealand Rebecca C. DidhamDavid M. ReithKen S. Harrison Report Pages: 163 - 167
Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant J.F.R. RobertsonA. HowellM.R. Lichinitser Report Pages: 169 - 174
Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology U. KumarS. I. GrigorakisS. Chaudhari Report Pages: 175 - 186
Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells Patricia D. SchleyHumberto B. JijonCatherine J. Field Report Pages: 187 - 195
On cancer incidence in multiple sclerosis and effects of immunomodulatory treatments Paul D. Feigin Letter to the editor Pages: 197 - 197